# Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL

> **NCT07072208** · NA · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 43 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Induction therapy-Pro regimen
- **DRUG:** Consolidation therapy-Pro-pola regimen

## Key facts

- **NCT ID:** NCT07072208
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07072208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07072208, "Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07072208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*